Events & Presentations

Investors

Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Jun 29, 2018 3:45 PM PDT
27th Annual Alpha-1 National Education Conference
San Francisco, CA
Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
Jun 20, 2018 9:00 AM EDT
JMP Securities Life Science Conference
New York, NY
Bruce Given, M.D., will present a corporate overview
Jun 15, 2018 2:15 PM EDT
Global Hepatitis Summit 2018
Toronto
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
Jun 8, 2018 5:30 PM SGT
The Science of HBV Cure 2018
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”
Jun 6, 2018 3:30 PM EDT
Jefferies 2018 Global Healthcare Conference
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
Jun 6, 2018 5:55 PM CEST
41st European Cystic Fibrosis Conference
Belgrade, Serbia
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled,“Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
May 21, 2018 9:15 AM PDT
American Thoracic Society (ATS) 2018 International Conference
San Diego
May 10, 2018 4:15 PM PDT
Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018
San Francisco
May 8, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Second Quarter Results
Apr 25, 2018 4:00 PM EDT
World Orphan Drug Congress USA 2018
Apr 12 - Apr 14, 2018
The EASL International Liver Congress™ 2018

Oral Presentations:

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection

  • Presentation Reference: PS-030
  • Session: Parallel session: Parallel session: HBV Cure: Pre-clinical studies
  • Date and Time: April 12, 2018 at 5:15 p.m. CET
  • Authors: Christine Wooddell, et al.

ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposure-response and efficacy in preclinical studies

  • Presentation Reference: PS-147
  • Session: Parallel session: Clinical developments in metabolic and rare disease
  • Date and Time: April 14, 2018 at 9:15 a.m. CET
  • Authors: Christine Wooddell, et al.

Poster Presentation:

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

  • Presentation Reference: FRI-362
  • Session: Viral hepatitis B/D: Therapy
  • Session Date and Time: April 13, 2018 from 9 a.m. to 5 p.m. CET
  • Authors: Man-Fung Yuen, et al.
Mar 22, 2018
American Society for Clinical Pharmacology & Therapeutics 2018 Annual Meeting
Mar 13, 2018 1:35 PM EDT
Barclays Global Healthcare Conference 2018
Miami
Feb 27 - Mar 1, 2018 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 22, 2018 3:10 PM UTC
SMI RNA Therapeutics Conference
London
Feb 9, 2018 4:30 PM EST
Arrowhead Fiscal 2018 First Quarter Results
Jan 8 - Jan 10, 2018 12:00 AM EST
JP Morgan Healthcare Conference Week
Dec 12, 2017 4:30 PM EST
Arrowhead Pharmaceuticals 2017 Fiscal Year End Results
Dec 5, 2017 6:10 PM HST
HEP DART 2017
Kona, Hawaii
Nov 28, 2017 9:30 AM EST
29th Annual Piper Jaffray Healthcare Conference
Nov 13 - Nov 15, 2017 12:00 AM EST
BIT's 8th World Gene Convention-2017
Macau, China
Oct 23, 2017
The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Disease
Washington, DC

Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT

  • Publication Number: LB-21
  • Session: Late-Breaking Poster Session
  • Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM

·        Authors: Christine I. Wooddell, et al.

Oct 10, 2017 10:45 AM EDT
Chardan Gene Therapy Conference
Sep 25, 2017 9:10 AM EDT
2017 Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017 1:00 PM EDT
Arrowhead Analyst R&D Day
Aug 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Third Quarter Results
May 5, 2017 11:30 AM CDT
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017 Scientific Sessions

Location: Minneapolis, MN

Title: Factor 12 RNAi-based therapeutic as a prophylactic anti-thrombotic therapy

May 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Second Quarter Results
Apr 19 - Apr 23, 2017 12:00 AM EDT
The EASL International Liver Congress™ 2017
Amsterdam, The Netherlands

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

  • Presentation Reference: PS-045
  • Session: Parallel session: Hepatitis B and D: Emerging treatment options
  • Date and Time: April 20, 2017 at 5:30 PM CET
  • Authors: Man-Fung Yuen, et al.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

  • Presentation Reference: THU-176
  • Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
  • Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
  • Authors: Edward Gane, et al.

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients

  • Presentation Reference: LBO-06
  • Session: Late Breaker session
  • Date and Time: April 22, 2017 at 5:15 PM CET
  • Authors: Alice Turner, et al.
Feb 21 - Feb 23, 2017 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 6, 2017 4:30 PM EST
Arrowhead Fiscal 2017 First Quarter Results
Dec 14, 2016 4:30 PM EST
Arrowhead Fiscal 2016 Year End Results
Nov 30, 2016 8:30 AM EST
The 28th Annual Piper Jaffray Healthcare Conference
New York

November 30, 8:30 a.m. EST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray.

Presentation Canceled

Nov 29, 2016 4:30 PM EST
Clinical Update Call
Nov 14, 2016 10:00 AM CST
American Heart Association's Scientific Sessions 2016
New Orleans

November 14, 10:40 a.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism”

November 14, 2:00 p.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)”

Nov 13, 2016
The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease
Boston

RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model

  • Publication Number: 124
  • Session: Parallel 19: Pediatric and Metabolic Liver Diseases: Basic and Translational
  • Session Date and Time: November 13, 2016 from 4:45 PM to 6:15 PM
  • Authors: Christine Wooddell, et al.

RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers

  • Publication Number: LB-24
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 13, 2016 from 8:00 AM to 5:30 PM

Authors: Alice Turner, et al.

Nov 7, 2016 11:30 AM MST
The 25th Annual Credit Suisse Healthcare Conference
Scottsdale, AZ

November 7, 11:30 a.m. MST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation.

Sep 29, 2016 6:00 AM PDT
Arrowhead/Amgen Collaboration Call
Sep 23, 2016 7:30 PM EDT
2016 International HBV Meeting
Seoul, Korea

September 24, 8:30 a.m. KST – Zhao Xu, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Functional HBsAg-encoding HBV fusion transcripts are produced from integrated HBV DNA in chronically infected chimpanzees - evidence from single molecule, real time (SMRT) sequencing”

Sep 14, 2016 4:30 PM EDT
7th Non-Coding RNA & RNAi Therapeutics Conference
Boston

September 14, 4:30 p.m. EDT – Erik Bush, Ph.D., Arrowhead director of extrahepatic targeting will deliver an oral presentation titled, “Targeted delivery strategies using Dynamic PolyconjugateTM (DPCTM) technology”

Sep 9, 2016 10:00 AM EDT
The 23rd Annual NewsMakers in the Biotech Industry
New York

September 9, 10:00 a.m. EDT – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation